Quantitative and Qualitative Disclosures about Market Risk
−Removed: Prior to July 15, 2019, our exposure to market risk due to changes in interest rates related primarily to the increase or decrease in the amount of interest expense from fluctuations in one-month LIBOR associated with
−Removed: our debt facility.
+Added: Prior to July 15, 2019, our exposure to market risk due to changes in interest rates related primarily to the increase or decrease in the amount of interest expense from
+Added: fluctuations in one-month LIBOR associated with our debt facility.
For each 1% increase in one-month LIBOR in excess of the floor of 2%, our annual interest expense would have increased by approximately $500,000.
−Removed: However, our Senior Secured Notes carry a 12.5% fixed interest rate per annum,
−Removed: thereby eliminating market risk due to changes in interest rates.
+Added: However, our Senior Secured Notes
+Added: carry a 12.5% fixed interest rate per annum, thereby eliminating market risk due to changes in interest rates.
Our cash and cash equivalents are maintained in FDIC protected accounts with no exposure to material changes in interest rates.
−Removed: At March 31, 2020, our interest rate on deposited cash
+Added: 30, 2020, our interest rate on deposited cash was 0.23%.
We do not purchase, sell or hold derivatives or other market risk sensitive instruments to hedge interest rate risk or for trading purposes.
−Removed: Further, we do not invest in any common stock or debt instruments that have been affected by the
−Removed: global COVID-19 outbreak which has resulted in material market movements during the quarter ended March 31, 2020.
−Removed: Our accounts receivables are concentrated predominantly with Indivior.
−Removed: With the recent launch of Sympazan, our concentration with three large national wholesalers of pharmaceutical products is not significant presently
−Removed: but may become so in future periods should Sympazan sales increase and should other pipeline products become approved by the FDA and become distributed through these three regional, or other, wholesalers.
−Removed: In the event of non-performance or
−Removed: non-payment by either Indivior or the wholesalers, there may be a material adverse impact on our financial condition, results of operations or net cash flow.
+Added: Further, we do not invest in any common stock or
+Added: debt instruments that have been affected by the global COVID-19 outbreak which has resulted in material market movements during the quarter ended June 30, 2020.
+Added: Our accounts receivables are concentrated predominantly with Indivior and also at June 30, 2020, Sunovion.
+Added: With the launch of Sympazan in 2018, our concentration with three
+Added: large national wholesalers of pharmaceutical products is not significant presently but may become so in future periods should Sympazan sales increase and should other pipeline products become approved by the FDA and become distributed through these
+Added: three regional, or other, wholesalers.
+Added: In the event of non-performance or non-payment by either Indivior or the wholesalers, there may be a material adverse impact on our financial condition, results of operations or net cash flow.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.